公司問答丨萬邦德:公司將根據醫藥大健康產業發展規劃持續推進新產品的研發
格隆匯5月6日丨有投資者在互動平台向萬邦德公司提問:公司剝離了鋁產品製造等非醫藥行業,然後現在醫藥研發投入金額不多,公司在研發上有什麼長期規劃?萬邦德迴應:公司2022年度研發費用與收入的比例較剝離鋁加工業務之前有較大提升。公司將根據醫藥大健康產業發展規劃持續推進新產品的研發,在中藥產品研發方面,加大公司自身研發力度的同時,將加強與中藥研發機構的戰略合作,提升公司中藥研發水平。公司目前在研產品項目,請您查看公司《2022年年度報吿》中“第三節 管理層討論與分析 二、報吿期內公司從事的主要業務”部分的內容。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.